CFO
CRSP icon

CVA Family Office’s CRISPR Therapeutics CRSP Stock Holding History

CVA Family Office’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273 Hold
5
– – ﹤0.01% 1757
2026
Q1 		$238 Buy
+5
New +$264 ﹤0.01% 1805
2024
Q1 		– Sell
-15
Closed -$939 – 1061
2023
Q4 		$939 Buy
+15
New +$829 ﹤0.01% 991

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CVA Family Office's CRSP Position: Q2 2026 in Review

CVA Family Office held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5 shares worth $273. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

CVA Family Office first reported a position in CRSP in Q4 2023 and has held it in 3 quarters since. The position peaked at $939 in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • CVA Family Office held 5 shares of CRISPR Therapeutics worth $273 as of Q2 2026.
  • CVA Family Office left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1757 holding.
  • CVA Family Office first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • CVA Family Office's CRISPR Therapeutics position peaked at $939 in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.